← All trials
NCT06911944
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2026
- Primary completion
- Dec 31, 2028
- Completion date
- Dec 31, 2028
- First posted
- Apr 4, 2025
- Last posted
- Nov 24, 2025
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Southern CaliforniaLead sponsor
- Alzheimer's Clinical Trial Consortium (ACTC)Collaborator
- Alzheimer's Therapeutic Research InstituteCollaborator
- University of Southern CaliforniaSponsor investigator
- Eli LillyCollaborator
- National Institute on Aging (NIA)Collaborator
- University of Southern CaliforniaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.